Toujeo is a long-acting insulin product developed by Sanofi, indicated for the treatment of diabetes mellitus in adults and children aged 6 and older [1]. It is a basal insulin, meaning it provides a steady background level of insulin throughout the day and night to help manage blood glucose [2].
What is Toujeo's active ingredient and how does it work?
Toujeo's active ingredient is insulin glargine [1]. It is a modified form of human insulin designed for prolonged action. Insulin glargine works by stimulating glucose uptake in peripheral tissues and by inhibiting hepatic glucose production, thereby lowering blood glucose levels [3]. It is administered via subcutaneous injection once daily [1].
When does Toujeo's patent exclusivity expire?
The patent landscape for Toujeo is complex and involves multiple patents related to its formulation, manufacturing, and use. DrugPatentWatch.com tracks these patents and their expiration dates. For precise details on Toujeo's patent expiries, one would typically consult specialized patent databases or resources like DrugPatentWatch.com [4].
How does Toujeo compare to other long-acting insulins?
Toujeo (insulin glargine 300 Units/mL) is a higher concentration formulation of insulin glargine compared to its predecessor, Lantus (insulin glargine 100 Units/mL) [2][5]. This higher concentration allows for a longer duration of action and a more stable pharmacokinetic profile, potentially leading to a more consistent glucose-lowering effect and reduced risk of nocturnal hypoglycemia in some patients [2][6]. Other long-acting insulins include insulin detemir (Levemir) and insulin degludec (Tresiba), each with its own unique pharmacokinetic and pharmacodynamic profiles [7].
What are the potential risks and side effects of Toujeo?
The most common side effects associated with Toujeo, as with all insulins, include hypoglycemia (low blood sugar), allergic reactions, injection site reactions (such as redness, swelling, or itching), and lipodystrophy (changes in fat tissue at the injection site) [1]. Hypoglycemia is the most frequent adverse event and can be serious, potentially leading to confusion, seizures, and even loss of consciousness [1][8]. It is crucial for patients to monitor their blood glucose levels regularly and to be aware of the signs and symptoms of hypoglycemia [8].
Can biosimilars of Toujeo be developed?
The development of biosimilars for biologic drugs like insulin glargine is possible once patent exclusivity and other market protections expire. Biosimilars are highly similar to the reference product and are approved by regulatory agencies based on rigorous scientific evidence demonstrating no clinically meaningful differences in safety, purity, and potency [9]. The introduction of biosimilars can increase competition and potentially lower costs for patients and healthcare systems. Information on the status of biosimilar development for Toujeo would be available through regulatory agencies and industry news [9].